Overview

Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women

Status:
Completed
Trial end date:
2009-01-21
Target enrollment:
Participant gender:
Summary
Open-label Phase IV trial of Letrozole 2,5mg po/day for 120 days prior to surgery for patients with locally advanced breast in postmenopausal women expressing hormonal receptors ( ER and PR)
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Letrozole